- ASP Isotopes has shipped **first samples of Ytterbium-176 and Silicon-28** to customers, with these two isotopes alone representing **$50 to $70 million** of potential revenues during **2026 and 2027**.  **[1921865_0001477932-25-006452_aspi_ex991.htm:1]** 
- The merger with Renergen is on track to close during **Q3 2025**, expected to deliver at least **$20 million in revenues during 2026** and be highly accretive to ASP Isotopes' financials.  **[1921865_0001477932-25-006452_aspi_ex991.htm:2]** **[1921865_0001477932-25-006452_aspi_ex991.htm:3]** 
- The company is transitioning to a commercial organization, with procurement underway for **four new laser production plants** to be constructed starting **Q1 2026**, and its subsidiary Quantum Leap Energy (QLE) targeting a public listing in **Q4 2025**.  **[1921865_0001477932-25-006452_aspi_ex991.htm:1]** 
- The combined group aims to generate over **$300 million in EBITDA in 2030**.  **[1921865_0001477932-25-006452_aspi_ex991.htm:3]**

ASP Isotopes Inc. Provides Q2 2025 Business and Strategic Update

- ASPI has shipped its **first samples of enriched silicon to a US-based customer** and is in the **final stages of reaching Ytterbium 176 production**.  **[1921865_tx_379611_2]** 
- The company signed a **large Memorandum of Understanding (MOU) with Fermi** for a joint venture to produce nuclear fuels, with ASPI planning to build a plant for strategically important isotope enrichment in Texas.  **[1921865_tx_379611_2]** 
- ASPI recently **listed on the Johannesburg Stock Exchange** and expects the **QLE spin-off to occur in the second half of the year**, potentially in **October or November**.  **[1921865_tx_379611_2]** **[1921865_tx_379611_5]** 
- The company reported approximately **$70,000,000 in cash on its balance sheet** last quarter, with a pro forma of **~$120,000,000**, and is seeking debt funding for the TerraPower plant by the **end of the calendar year**.  **[1921865_tx_379611_12]** 
- The acquisition of Renogen aims to create a **vertically and horizontally integrated critical materials business**, leveraging Renogen's helium supply and access to **low-cost natural gas at $0.35 per MMBtu** in South Africa.  **[1921865_tx_379611_5]** **[1921865_tx_379611_8]**

ASPI Provides Updates on Strategic Partnerships, Isotope Production, and Financials

- ASP Isotopes Inc. (ASPI) is preparing for a **secondary listing on the Johannesburg Stock Exchange (JSE)**, with trading expected to commence on **August 27, 2025**, while retaining its primary Nasdaq listing.  **[1921865_0001477932-25-006215_aspi_8k.htm:1]** 
- The company commenced commercial production of **Silicon-28** in **late March 2025**, shipping its first samples to a US customer in **August 2025**.  **[1921865_0001477932-25-006215_aspi_8k.htm:1]** 
- Commercial production of **Ytterbium-176** began in **April 2025**, with the first batch of final product expected in **late August 2025**; however, the transition to a semi-continuous processing method is delayed to **late Q3 or early Q4 2025**.  **[1921865_0001477932-25-006215_aspi_8k.htm:1]** 
- ASPI is enriching **Carbon-12 to 99.99%** for a US customer, with the first commercial product expected in **September 2025**, following a 10-day delay due to regulatory inspections.  **[1921865_0001477932-25-006215_aspi_8k.htm:2]** 
- The company expects to initiate the spin-out of its subsidiary, Quantum Leap Enrichment (QLE), as a standalone public company in the **second half of 2025**, and anticipates the Renergen acquisition to close during the **third quarter of 2025**.  **[1921865_0001477932-25-006215_aspi_8k.htm:2]**

ASP Isotopes (ASPI)